πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9359290

Treatment of cataplexy

Jazz Pharmaceuticals International III Limited Β· Granted Tue Jun 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9358249

Use of Pateamine A for the treatment of age-related muscle wasting

The Regents of the University of California Β· Granted Tue Jun 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9352019

Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment mo

University of Connecticut Health Center Β· Granted Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9351989

Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for tr

University College Cardiff Consultants Limited Β· Granted Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9351960

Agent for the treatment of viral hepatitis C

OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU β€œPHARMENTERPRISES” Β· Granted Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9340782

Antimir-451 for the treatment of polycythemias

The Board of Regents of the University of Texas System Β· Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9339515

Method for treatment of pulmonary fibrosis

GALECTIN THERAPEUTICS, INC. Β· Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9339491

Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructiv

MEREO BIOPHARMA 1 LIMITED Β· Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9334246

Substituted triazines for malaria treatment and chemoprophylaxis

The United States of America, as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research Β· Granted Tue May 10 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9334250

Multifunctional radical quenchers for the treatment of mitochondrial dysfunction

ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Tue May 10 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9333244

Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for

HALOZYME, INC. Β· Granted Tue May 10 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9333171

Controlled-release CNS modulating compositions and methods for the treatment of otic disor

The Regents of the University of California Β· Granted Tue May 10 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9328387

Antipsychotic treatment based on SNP genotype

VANDA PHARMACEUTICALS INC. Β· Granted Tue May 03 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9327023

HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue May 03 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9320786

Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9314448

Method of inhibiting ABCG2 and other treatment methods

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9314507

Methods of treatment of heart failure with natriuretic peptides

Capricor Therapeutics, Inc. Β· Granted Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9303077

Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity

Soricimed Biopharma Inc. Β· Granted Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9303044

7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-A]pyrimidin-5-ones for the treatment of throm

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9301947

Ryanodine receptor inhibitors for treatment of T-cell mediated disorders

The Regents of the University of California Β· Granted Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9303066

Treatments for gastrointestinal disorders

IRONWOOD PHARMACEUTICALS, INC. Β· Granted Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9295674

Metalloporphyrin neurological treatments

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Mar 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9290474

Methods for making and using novel semi-synthetic small molecules for the treatment parasi

The Regents of the University of California Β· Granted Tue Mar 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9289513

Targeted cytokine for treatment of musculoskeletal diseases

OPTION PHARMACEUTICALS, LLC Β· Granted Tue Mar 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted